share_log

Biodexa Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Biodexa Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Biodexa Pharmaceuticals | 6-K：外國發行人報告
美股sec公告 ·  05/01 01:16
牛牛AI助理已提取核心訊息
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company listed on NASDAQ as BDRX, has announced that its licensor Emtora Biosciences will present the results of a Phase 2 clinical trial of eRapa for Familial Adenomatous Polyposis (FAP) at the Digestive Disease Week annual meeting in Washington DC, scheduled for May 18-21, 2024. The trial's six-month data will be presented by Principal Investigator Carol Burke, MD. Biodexa had previously announced on April 26, 2024, an exclusive worldwide licensing agreement with Emtora for the development and commercialization of eRapa. eRapa, a proprietary oral tablet formulation of rapamycin, is designed to improve bioavailability and reduce toxicity. It has been granted Orphan Designation in the US for FAP, a condition characterized by the proliferation of polyps in the colon and/or rectum that can lead to cancer if untreated. Biodexa's pipeline also includes tolimidone for type 1 diabetes and MTX110 for rare/orphan brain cancer indications. The company is headquartered in Cardiff, UK, and focuses on developing innovative products for diseases with unmet medical needs.
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company listed on NASDAQ as BDRX, has announced that its licensor Emtora Biosciences will present the results of a Phase 2 clinical trial of eRapa for Familial Adenomatous Polyposis (FAP) at the Digestive Disease Week annual meeting in Washington DC, scheduled for May 18-21, 2024. The trial's six-month data will be presented by Principal Investigator Carol Burke, MD. Biodexa had previously announced on April 26, 2024, an exclusive worldwide licensing agreement with Emtora for the development and commercialization of eRapa. eRapa, a proprietary oral tablet formulation of rapamycin, is designed to improve bioavailability and reduce toxicity. It has been granted Orphan Designation in the US for FAP, a condition characterized by the proliferation of polyps in the colon and/or rectum that can lead to cancer if untreated. Biodexa's pipeline also includes tolimidone for type 1 diabetes and MTX110 for rare/orphan brain cancer indications. The company is headquartered in Cardiff, UK, and focuses on developing innovative products for diseases with unmet medical needs.
在納斯達克上市的臨床階段生物製藥公司Biodexa Pharmicals PLC宣佈，其許可方Emtora Biosciences將在定於2024年5月18日至21日在華盛頓特區舉行的消化疾病週年會上公佈eRapa治療家族性腺瘤性息肉病（FAP）的2期臨床試驗結果。該試驗的六個月數據將由首席研究員卡羅爾·伯克醫學博士公佈。Biodexa此前曾於2024年4月26日宣佈與Emtora簽訂全球獨家許可協議，用於eRapa的開發和商業化。eRapa是雷帕黴素的專有口服片劑配方，旨在提高生物利用度並降低毒性。FAP 在美國被授予孤兒稱號，這種疾病的特徵是結腸和/或直腸中的息肉增生，如果不進行治療，可能會導致癌症。Biodexa 的產品線還包括用於 1 型糖尿病的託利米酮和用於罕見/孤兒腦癌適應症的 MTX110。該公司總部位於英國加的夫，專注於爲醫療需求未得到滿足的疾病開發創新產品。
在納斯達克上市的臨床階段生物製藥公司Biodexa Pharmicals PLC宣佈，其許可方Emtora Biosciences將在定於2024年5月18日至21日在華盛頓特區舉行的消化疾病週年會上公佈eRapa治療家族性腺瘤性息肉病（FAP）的2期臨床試驗結果。該試驗的六個月數據將由首席研究員卡羅爾·伯克醫學博士公佈。Biodexa此前曾於2024年4月26日宣佈與Emtora簽訂全球獨家許可協議，用於eRapa的開發和商業化。eRapa是雷帕黴素的專有口服片劑配方，旨在提高生物利用度並降低毒性。FAP 在美國被授予孤兒稱號，這種疾病的特徵是結腸和/或直腸中的息肉增生，如果不進行治療，可能會導致癌症。Biodexa 的產品線還包括用於 1 型糖尿病的託利米酮和用於罕見/孤兒腦癌適應症的 MTX110。該公司總部位於英國加的夫，專注於爲醫療需求未得到滿足的疾病開發創新產品。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。